Pasithea Therapeutics (KTTA) News Today $1.38 +0.01 (+0.73%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$1.38 0.00 (-0.36%) As of 04/17/2025 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Pasithea Reports Positive Safety Review Committee Recommendation From Phase 1 Study Of PAS-004April 11, 2025 | nasdaq.comPasithea Therapeutics Leads Healthcare Buzz Surge As Cancer Trial Clears Safety Hurdle, Moves To Next Dosing CohortApril 11, 2025 | msn.comPasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced CancerApril 10, 2025 | globenewswire.comPasithea Therapeutics to Present at the 2025 CAGLA NeauxCancer ConferenceMarch 24, 2025 | finance.yahoo.comKTTA stock touches 52-week low at $1.32 amid market challengesFebruary 12, 2025 | msn.comPasithea Therapeutics Shares Rise After Positive Safety Review for Cancer TreatmentFebruary 6, 2025 | marketwatch.comPasithea announces Safety Review Committee recommendationFebruary 6, 2025 | markets.businessinsider.comBig Mid-Week Move From This Small BiotechFebruary 6, 2025 | msn.comPasithea's PAS-004 advances in cancer trial with no toxicitiesFebruary 6, 2025 | msn.comPasithea Therapeutics Advances PAS-004 Clinical Trial to Next Dose Level Following Safety Review Committee RecommendationFebruary 5, 2025 | quiverquant.comPasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced CancerFebruary 5, 2025 | globenewswire.comKTTA stock touches 52-week low at $2.19 amid market challengesJanuary 31, 2025 | msn.comPasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4January 14, 2025 | globenewswire.comPasithea Therapeutics announces SRC recommended proceeding to cohort 4November 20, 2024 | markets.businessinsider.comPasithea Therapeutics Advances PAS-004 Clinical Trial to Next Dose Level Following Positive Safety Review FindingsNovember 20, 2024 | quiverquant.comPasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced CancerNovember 20, 2024 | globenewswire.comCrude Oil Down Over 2%; US Initial Jobless Claims FallSeptember 27, 2024 | msn.comDow Surges Over 250 Points; Accenture Earnings Top ViewsSeptember 27, 2024 | benzinga.comPasithea Therapeutics Shares Move Higher After Positive Data for Cancer TreatmentSeptember 26, 2024 | marketwatch.comPasithea Announces Positive Initial Data From Phase 1 Trial Of PAS-004 In Advanced Cancer; Stock UpSeptember 26, 2024 | markets.businessinsider.comPasithea Therapeutics (NASDAQ:KTTA) Stock Quotes, Forecast and News SummarySeptember 26, 2024 | benzinga.comPasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq RulesSeptember 26, 2024 | globenewswire.comPasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced CancerSeptember 26, 2024 | globenewswire.comPasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity StudiesSeptember 9, 2024 | globenewswire.comPasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory BoardSeptember 3, 2024 | globenewswire.comPasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceAugust 28, 2024 | globenewswire.comKTTA Stock Earnings: Pasithea Therapeutics Reported Results for Q4 2023June 25, 2024 | investorplace.comPasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual MeetingMay 28, 2024 | globenewswire.comKTTA Stock Earnings: Pasithea Therapeutics Reported Results for Q1 2024May 15, 2024 | msn.comPasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual MeetingApril 29, 2024 | globenewswire.comPasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated CancersApril 24, 2024 | globenewswire.comTrading was temporarily halted for "KTTA" at 02:02 PM with a stated reason of "LULD pause."February 15, 2024 | marketbeat.comPasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004February 13, 2024 | finance.yahoo.comPasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) PositionJanuary 8, 2024 | finance.yahoo.comPasithea Jumps as FDA Grants IND Status to Cancer TreatmentJanuary 2, 2024 | msn.comPasithea Therapeutics' IND Application For PAS-004 Gets FDA AcceptanceJanuary 2, 2024 | markets.businessinsider.comPasithea conducts 1-for-20 reverse stock split, gets FDA okay for studyJanuary 2, 2024 | seekingalpha.comPasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer PatientsJanuary 2, 2024 | finance.yahoo.comPasithea Therapeutics Stock (NASDAQ:KTTA) Dividends: History, Yield and DatesJanuary 1, 2024 | benzinga.comTrading was temporarily halted for "KTTA" at 07:12 PM with a stated reason of "News pending."January 1, 2024 | marketbeat.comPasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023December 28, 2023 | finance.yahoo.comPasithea Therapeutics Announces Results from 2023 Annual MeetingDecember 19, 2023 | finance.yahoo.comWhy Is Pasithea Therapeutics (KTTA) Stock Down 12% Today?December 13, 2023 | msn.comNeurology Focused Pasithea Therapeutics Stock Soars Over 150% Today - Here's WhyDecember 11, 2023 | msn.comPasithea Announces Positive In Vivo Preclinical Data For PAS-004December 11, 2023 | markets.businessinsider.comPasithea stock soars as high as 190% on preclinical dataDecember 11, 2023 | msn.comWhy Is Pasithea Therapeutics (KTTA) Stock Up 105% Today?December 11, 2023 | investorplace.comPasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft ModelsDecember 11, 2023 | finance.yahoo.comPasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of StockholdersNovember 29, 2023 | finance.yahoo.comPasithea stock jumps 12% on update for anti-tumor drug PAS-004November 29, 2023 | msn.com Get Pasithea Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KTTA and its competitors with MarketBeat's FREE daily newsletter. Email Address KTTA Media Mentions By Week KTTA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KTTA News Sentiment▼-1.000.58▲Average Medical News Sentiment KTTA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KTTA Articles This Week▼10▲KTTA Articles Average Week Get Pasithea Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KTTA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BriaCell Therapeutics News Calidi Biotherapeutics News MEI Pharma News Cocrystal Pharma News Cellectar Biosciences News 23andMe News IN8bio News Imunon News ImmunoPrecise Antibodies News Marker Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KTTA) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump’s Top Secret $9 Trillion AI SuperweaponJeff Brown spotted Nvidia at $1. Now he’s revealing a new AI superweapon — and the Musk-connected stocks that ...Brownstone Research | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pasithea Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pasithea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
